Agios’ oral drug se­cures PhI­II suc­cess in trans­fu­sion-in­de­pen­dent tha­lassemia pa­tients

Agios Phar­ma­ceu­ti­cals’ oral drug can­di­date is a step clos­er to mar­ket af­ter it suc­ceed­ed in a late-stage study in tha­lassemia pa­tients who don’t need reg­u­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER